While many know that antibodies attack foreign bacteria and viruses, scientists today are also engineering antibodies to target cancer cells. Just recently, Sir Gregory P. Winter, CBE, FRS, FMedSci, received the 2018 Nobel Prize for Chemistry (along with Frances H. Arnold, Ph.D. and George P. Smith, Ph.D.) for the use of phage display to direct the evolution of antibodies in order to create new cancer drugs.
Targeted antibodies are a special type of protein designed to target antigens, or markers, located on the surface of cancer cells. Once the antibodies locate antigens, they can recruit immune cells to attack or interfere with cell signaling, helping to block growth and communication of tumor cells.
In this webinar for patients and caregivers, Rony Dahan, Ph.D., of Weizmann Institute of Science (Israel) discusses the latest advances in targeted antibodies for the effective treatment of many forms of cancer.
Dr. Dahan completed his PhD in Molecular Immunology at the Technion in 2010. He served as a postdoctoral fellow in Cancer Immunology at the Laboratory of Jeffrey Ravetch, M.D., Ph.D., at Rockefeller University in New York from 2013 until joining the faculty of the Weizmann Institute of Science in August 2017. Rony Dahan’s Lab in the Department of Immunology at Weizmann Institute of Science studies antibody effector functions in cancer immunology and immunotherapy.
The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune.
Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series.